Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (FXS), today announced that it will report its financial results for the second quarter ended June 30, 2015 before the market open, and will host a corporate update conference call and webcast on Thursday, August 13 at 8:30 am Eastern Time.
|Conference Call & Webcast|
|Thursday, August 13th @ 8:30am Eastern Time/5:30am Pacific Time|
|Replays available through August 27, 2015|
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and Fragile X Syndrome. For more information please visit the Company’s website,www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contact LifeSci Advisors, LLC Michael Rice 646-597-6979 email@example.com Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 firstname.lastname@example.org Israel Investor Contact Alcobra Investor Relations Debbie Kaye +972-72 2204661 email@example.com